- (Waltham, Massachusetts) is a medical device and pharmaceutical company developing technology for corneal crosslinking. The companyís products are used to treat a number of pathologies as well as to enhance Lasik procedure outcomes. Avedro markets several products in Europe and is in late-stage clinical trials in the US.
- (London, UK) is a new company focusing on clinical co-development and financing of late-stage therapeutics. The company will use its clinical development and regulatory expertise to obtain global approvals for a broad range of drugs and biologics.
- eFFECTOR Therapeutics
- (San Diego, California) is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis), with an initial emphasis on cancer. Kevan Shokat, ex Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders.
- GenSight Biologics
- (Paris, France) is developing ophthalmic therapeutics using gene therapy. The company is focused on a gene replacement therapy for Leberís hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa. The lead product is expected to enter clinical trials later in 2013 in LHON patients.
(Dates in brackets indicate when the first investment was made.)